Beddow Capital Management Inc. Has $8.52 Million Position in Johnson & Johnson (JNJ)

Beddow Capital Management Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the 1st quarter, HoldingsChannel reports. The firm owned 66,447 shares of the company’s stock after selling 800 shares during the period. Johnson & Johnson makes up 3.4% of Beddow Capital Management Inc.’s investment portfolio, making the stock its 13th biggest position. Beddow Capital Management Inc.’s holdings in Johnson & Johnson were worth $8,515,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Goodman Financial Corp acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $104,000. Stelac Advisory Services LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $108,000. Princeton Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $141,000. Price Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $148,000. Finally, Smart Portfolios LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $150,000. 66.22% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson opened at $130.75 on Friday, Marketbeat.com reports. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.32. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $351.92 billion, a PE ratio of 17.91, a PEG ratio of 2.00 and a beta of 0.73.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The business had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the previous year, the business earned $1.83 EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 8.14 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.75%. The ex-dividend date is Monday, August 27th. Johnson & Johnson’s payout ratio is currently 49.32%.

Several research analysts have recently issued reports on the company. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Monday, April 16th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 price objective (down from $175.00) on shares of Johnson & Johnson in a research report on Wednesday, April 18th. They noted that the move was a valuation call. Stifel Nicolaus lowered their price objective on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Wednesday, April 18th. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 18th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $142.63.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply